Bluebird Bio Inc. (BLUE) Is Up Sharply On Multiple Myeloma Study Results

Shutterstock photo

( - bluebird bio Inc. ( BLUE ) announced Thursday morning that interim data from its ongoing Phase 1 clinical study of bb2121, will be presented today at the 28th EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium in Munich, Germany.

Chief Medical Officer David Davidson
, M.D. stated, "early data from our ongoing Phase 1 study of bb2121 demonstrate objective anti-tumor responses in heavily pre-treated patients with multiple myeloma, with all patients in the 15.0 x 107 and 45.0 x 107 CAR+ T cell dose cohorts achieving responses."

bluebird bio has gapped open sharply higher this morning and is now up 14.55 at $74.90 on above average volume. The stock has jumped to over a month and a half high.

This article appears in: Technology
Referenced Symbols: BLUE

More from RTT News


See headlines for BLUE

Follow on: